Research Interests
- Outcomes and novel biomarkers in patients with heart failure undergoing surgery
- Modification of pulmonary circulation for perioperative end-organ protection
- Thromboinflammation in lung injury and extracorporeal life support
- Thromboembolic events after treatment for acquired bleeding disorders in cardiovascular surgery
Selected Grants
Trajectories of Recovery after Intravenous propofol versus inhaled VolatilE anesthesia: THRIVE Trial
ResearchPrincipal Investigator · Awarded by University of Michigan · 2023 - 2026ATN-108
Clinical TrialPrincipal Investigator · Awarded by Octapharma AG · 2024 - 2026Prospective, multicentre, active-control randomised trial comparing 4-factor prothrombin complex concentrate with frozen plasma in bleeding adult cardiac surgical patients
Clinical TrialPrincipal Investigator · Awarded by Octapharma AG · 2022 - 2025Right Ventricular Metabolic Dysregulation after Surgery for Heart Failure
ResearchPrincipal Investigator · Awarded by International Anesthesia Research Society · 2021 - 2023LEX-209 Octapharma
Clinical TrialPrincipal Investigator · Awarded by Octapharma AG · 2017 - 2018Fellowships, Gifts, and Supported Research
Integrated Training in Anesthesiology & Critical Care Research ·
February 2018
- February 2021
Awarded by: NIH T32 GM008600
INSPIRE-FLO: Inhaled Selective Pulmonary Vasodilation for Advanced Heart Failure Therapies and Lung Transplantation Outcomes ·
May 2017
- December 2021
Principal Investigator ·
Awarded by: Duke University Health System
Randomized, controlled, triple-blinded trial comparing the ability of inhaled nitric oxide and aerosolized epoprostenol with extended stability (iPGI2,Veletri®) to reduce the incidence of (1) right-sided heart failure after advanced left-heart replacement therapies (durable LVAD, heart transplantation); and (2) severe primary graft dysfunction after lung transplantation.
External Relationships
- Anesthesia Labs
- Octapharma
- Patient Centered Outcomes Research Institute
- UpToDate, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.